Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Coates, LC, Tillett, W, D'Agostino, MA et al. (8 more authors) (2022) Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. The Lancet Rheumatology, 4 (4). e262-e273. ISSN 2665-9913

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2022 The Author(s). This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/)
Dates:
  • Accepted: 7 January 2022
  • Published (online): 25 February 2022
  • Published: 1 April 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Musculoskeletal Medicine & Imaging (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 10 May 2022 10:01
Last Modified: 16 May 2022 07:45
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S2665-9913(22)00008-X

Share / Export

Statistics